STRO

STORYSTOCKS ANALYST NOTE: STRO (Sutro Biopharma, Inc.) Date: 2026-06-20 Analyst: StoryStocks-Native Equity Analyst

1. Structural Readiness

Conservative Entry: $13.82 Current Price: $29.63 Extension: +114.4% vs. conservative entry

Analysis:

2. The Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Oncology (Tier Direct, High Confidence). Thesis Context: Sutro Biopharma is positioned as a direct beneficiary within the Oncology sector, specifically leveraging the broader secular trend of antibody-drug conjugate (ADC) development. While the "GLP-1" tag in the secular theme list is present, the company's specific role is defined by its ADC platform rather than direct GLP-1 exposure. The company operates in a high-growth environment where the American Cancer Society estimated over 2 million new cancer cases in the U.S. in 2026. The thesis relies on the structural shift toward site-specific, novel-format ADCs, which have shown promise with fourteen currently marketed products in the U.S. as of this date. The company's direct beneficiary status is derived from its proprietary technology addressing a massive, growing addressable market.

3. The Business

Company Overview: Sutro Biopharma, Inc. is an oncology company developing site-specific and novel-format antibody drug conjugates (ADCs). The business model relies on internal R&D to advance a pipeline of ADC candidates, supplemented by strategic collaborations and licensing agreements that provide upfront payments and milestone revenues.

Operational Status (as of 2026-06-20):

• Pipeline Progress: The company has successfully advanced its lead candidate, STRO-004. An Investigational New Drug (IND) application was filed and cleared in October 2025, with Phase 1 trial initiation occurring in November 2025. As of the latest reporting, the company finished dosing patients in dose level 2 in February 2026 and began dosing in dose level 3 in the same month. Management expects to report initial data from this trial in mid-2026.
• Future Pipeline: IND-enabling activities are underway for STRO-006, with a potential IND filing expected in 2026. Additionally, CMC activities for a PTK7-targeting dual-payload ADC are in progress, with an anticipated IND filing in late 2026 or early 2027.
• Financial Position: As of March 31, 2026, the Company held $202.6 million in unrestricted cash, cash equivalents, and marketable securities. Management stated that these funds are available to fund future operations and are sufficient to maintain operations for at least 12 months following the filing date of the interim financial statements.
• Collaboration Revenue: Through December 31, 2025, the Company had received an aggregate of approximately $1.016 billion in payments from collaborations, including roughly $79 million in equity investments. A notable component of this history includes a $90.0 million nonrefundable upfront payment received from Astellas in 2022.

4. Archetype and Conviction

Archetype: Growth Leader Rationale: The company fits the Growth Leader archetype due to its active clinical progression (Phase 1 dosing in multiple cohorts), the expansion of its pipeline (STRO-006 and PTK7 programs), and the validation of its platform through significant collaboration revenue ($1B+ aggregate). The business is not in a deep value recovery or defensive operator mode; it is in a high-growth phase of clinical execution and platform validation.

Conviction Stack:

• Thesis Strength: High. The company is a direct play on the ADC secular theme, which is supported by a large and growing patient population (2M+ new cases in 2026).
• Evidence Quality: Strong. The evidence base includes specific clinical milestones (IND clearance, dosing completion) and robust financial disclosures confirming liquidity ($202.6M cash) and a runway of at least 12 months.
• Setup Readiness: The coil is confirmed and active with a massive extension (+114.4%). The setup is fully formed, with the breakout having fired and the price holding well above the stop.
• Rerating Potential: Significant. The upcoming data readout for STRO-004 (expected mid-2026) and the potential IND filings for STRO-006 and the PTK7 program provide multiple catalysts for re-rating the stock from a clinical-stage biotech to a potential commercial or advanced-stage asset.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: Failure to report initial data from the STRO-004 Phase 1 trial by mid-2026, or negative safety/efficacy signals from the dose level 2 or 3 cohorts, would materially weaken the thesis.
• Liquidity: A significant reduction in cash reserves below the 12-month runway threshold without new capital raises would threaten operations.

Strengtheners:

• Clinical: Positive initial data readout from STRO-004 in mid-2026.
• Strategic: Successful IND filing for STRO-006 in 2026 or the PTK7 program in late 2026/early 2027.
• Financial: Announcement of a new collaboration or milestone payment exceeding current cash burn projections.

Evidence Gaps:

• Commercialization Timeline: No evidence is currently available regarding the timeline for Phase 2 initiation or potential commercial launch, as the company is still in Phase 1.
• Specific Efficacy Metrics: While dosing is complete, specific efficacy data (e.g., response rates) for STRO-004 is not yet public as of the mid-2026 data readout expectation; the market is currently pricing in the *expectation* of data, not the data itself.
• Cash Burn Rate: While total cash is known ($202.6M), the specific quarterly burn rate is not explicitly detailed in the provided evidence, making precise runway calculation dependent on management's 12-month statement.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key risks: Extreme ATR volatility (>9%) leading to sharp drawdowns; binary clinical data risk for STRO-004; potential dilution if cash runway extends beyond 12 months without new capital. Sizing hint: Reduce position size relative to standard growth leaders due to extreme volatility bucket, but maintain core conviction on the setup structure. Expected path: Management expects to report initial STRO-004 data mid-2026; subsequent IND filings for STRO-006 and PTK7 programs expected in late 2026/early 2027; price likely to trend higher on positive data confirmation. Expected horizon: 6 to 12 months for the primary data catalyst to resolve.